These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28480267)

  • 21. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses.
    Cornely OA; Vehreschild MJGT; Adomakoh N; Georgopali A; Karas A; Kazeem G; Guery B
    Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1187-1194. PubMed ID: 30911926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.
    Nelson RL; Kelsey P; Leeman H; Meardon N; Patel H; Paul K; Rees R; Taylor B; Wood E; Malakun R
    Cochrane Database Syst Rev; 2011 Sep; (9):CD004610. PubMed ID: 21901692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.
    Bricker E; Garg R; Nelson R; Loza A; Novak T; Hansen J
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004610. PubMed ID: 15674956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review.
    Al Momani LA; Abughanimeh O; Boonpheng B; Gabriel JG; Young M
    Cureus; 2018 Jun; 10(6):e2778. PubMed ID: 30112254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain.
    Reigadas E; Alcalá L; Marín M; Pelaéz T; Martin A; Iglesias C; Bouza E
    J Antimicrob Chemother; 2015 Aug; 70(8):2311-5. PubMed ID: 25876881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study.
    Musher DM; Logan N; Bressler AM; Johnson DP; Rossignol JF
    Clin Infect Dis; 2009 Feb; 48(4):e41-6. PubMed ID: 19133801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial.
    Gerding DN; Meyer T; Lee C; Cohen SH; Murthy UK; Poirier A; Van Schooneveld TC; Pardi DS; Ramos A; Barron MA; Chen H; Villano S
    JAMA; 2015 May; 313(17):1719-27. PubMed ID: 25942722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection.
    Zhanel GG; Walkty AJ; Karlowsky JA
    Can J Infect Dis Med Microbiol; 2015; 26(6):305-12. PubMed ID: 26744587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.
    Nelson R
    Cochrane Database Syst Rev; 2007 Jul; (3):CD004610. PubMed ID: 17636768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial.
    Hota SS; Sales V; Tomlinson G; Salpeter MJ; McGeer A; Coburn B; Guttman DS; Low DE; Poutanen SM
    Clin Infect Dis; 2017 Feb; 64(3):265-271. PubMed ID: 28011612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update of treatment algorithms for Clostridium difficile infection.
    Ooijevaar RE; van Beurden YH; Terveer EM; Goorhuis A; Bauer MP; Keller JJ; Mulder CJJ; Kuijper EJ
    Clin Microbiol Infect; 2018 May; 24(5):452-462. PubMed ID: 29309934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
    Cornely OA
    Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
    Cornely OA; Crook DW; Esposito R; Poirier A; Somero MS; Weiss K; Sears P; Gorbach S;
    Lancet Infect Dis; 2012 Apr; 12(4):281-9. PubMed ID: 22321770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile.
    Alam MZ; Wu X; Mascio C; Chesnel L; Hurdle JG
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5165-70. PubMed ID: 26055381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
    Johnson S; Louie TJ; Gerding DN; Cornely OA; Chasan-Taber S; Fitts D; Gelone SP; Broom C; Davidson DM;
    Clin Infect Dis; 2014 Aug; 59(3):345-54. PubMed ID: 24799326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of vancomycin dose on treatment outcomes in severe Clostridium difficile infection.
    Lam SW; Bass SN; Neuner EA; Bauer SR
    Int J Antimicrob Agents; 2013 Dec; 42(6):553-8. PubMed ID: 24103633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged oral vancomycin for secondary prophylaxis of relapsing Clostridium difficile infection.
    Zhang K; Beckett P; Abouanaser S; Stankus V; Lee C; Smieja M
    BMC Infect Dis; 2019 Jan; 19(1):51. PubMed ID: 30642269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial.
    Lee CH; Steiner T; Petrof EO; Smieja M; Roscoe D; Nematallah A; Weese JS; Collins S; Moayyedi P; Crowther M; Ropeleski MJ; Jayaratne P; Higgins D; Li Y; Rau NV; Kim PT
    JAMA; 2016 Jan; 315(2):142-9. PubMed ID: 26757463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral Vancomycin Monotherapy Versus Combination Therapy in Solid Organ Transplant Recipients With Uncomplicated Clostridium difficile Infection: A Retrospective Cohort Study.
    Korayem GB; Eljaaly K; Matthias KR; Zangeneh TT
    Transplant Proc; 2018; 50(1):137-141. PubMed ID: 29407296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
    Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.